DnB Asset Management AS raised its position in Amgen, Inc. (NASDAQ:AMGN) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,705 shares of the medical research company’s stock after purchasing an additional 839 shares during the quarter. DnB Asset Management AS’s holdings in Amgen were worth $13,339,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in AMGN. Janus Henderson Group PLC increased its stake in shares of Amgen by 3,664.7% in the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after purchasing an additional 3,601,087 shares during the period. FMR LLC increased its stake in shares of Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after purchasing an additional 2,587,041 shares during the period. Renaissance Technologies LLC increased its stake in shares of Amgen by 40.9% in the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after purchasing an additional 986,700 shares during the period. BlackRock Inc. increased its stake in shares of Amgen by 1.9% in the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after purchasing an additional 909,689 shares during the period. Finally, Nordea Investment Management AB increased its stake in shares of Amgen by 12.9% in the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares during the period. Institutional investors own 78.95% of the company’s stock.

Several equities research analysts have commented on the stock. Mizuho restated a “buy” rating and issued a $200.00 price target (up previously from $192.00) on shares of Amgen in a research note on Monday. Leerink Swann restated a “market perform” rating on shares of Amgen in a research note on Friday, February 2nd. Morgan Stanley decreased their price objective on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a report on Friday, February 2nd. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Royal Bank of Canada decreased their price objective on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a report on Thursday, October 26th. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $191.84.

In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the sale, the executive vice president now directly owns 56,106 shares in the company, valued at $9,921,223.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.19% of the company’s stock.

Shares of Amgen, Inc. (AMGN) opened at $179.52 on Thursday. The firm has a market cap of $130,320.00, a P/E ratio of 69.58, a P/E/G ratio of 2.15 and a beta of 1.42. Amgen, Inc. has a 1-year low of $152.16 and a 1-year high of $201.23. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.89 earnings per share. equities research analysts predict that Amgen, Inc. will post 13.22 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.94%. This is a boost from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 178.29%.

Amgen announced that its Board of Directors has authorized a share buyback program on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: “DnB Asset Management AS Has $13.34 Million Holdings in Amgen, Inc. (AMGN)” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/02/15/dnb-asset-management-as-has-13-34-million-holdings-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.